Moreover, being PKCs widely recognized as RAS-independent substrates, the identification of PKCε as a hub molecule at the crossroad of signaling networks governing the main tumor malignant hallmarks in PDAC could represent an important advance towards innovative target therapeutic strategies overcoming RAS. The gene discussed is PRKCE; the disease is neoplasm.